Clinical trials: Stroke Assessment
Muscle Spasticity
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)
The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity
- Trial name
- NCT03289702
- Testing
- CORETOX®, BOTOX®
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Medy-Tox
Acute Ischemic Stroke
A Single Ascending Dose of HRS-4029 in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
- Trial name
- NCT06905314
- Testing
- HRS-4029
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
- Trial name
- BRIGHT (NCT05403866)
- Testing
- LT3001 Drug Product
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Stroke
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and…
- Trial name
- NCT04002700
- Testing
- Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
- Where
- United States
- Volunteers
- 1,234,412 people
- Sponsor
- Janssen Research & Development, LLC
Acute Ischemic Stroke
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of GM1 injection in the treatment of patients with acute ischemic stroke.
- Trial name
- NCT06742216
- Testing
- Monosialoganglioside
- Where
- China
- Volunteers
- 1,232 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
- Trial name
- NCT03062397
- Testing
- JPI-289 Low-dose, JPI-289 High-dose
- Where
- 15 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Neuroprotection in Acute Cerebral Ischemia II
The goal of this clinical trial is to evaluate whether low-frequency, low-intensity transcranial magnetic stimulation (ELF-MF), delivered by the I-NIC medical device, is effective and safe in treating patients with acute ischemic…
- Trial name
- NCT07552818
- Testing
- Treatment with the I-NIC medical device for neuroprotection
- Volunteers
- 364 people
- Sponsor
- IGEA
Stroke, Gait, Hemiplegic
Evaluation of the Safety and Usability of the MAK Exoskeleton in Patients With Stroke
This study aims to evaluate the safety and usability of a motorized mobility assistance exoskeleton (MAK). The procedure explores the use of the MAK exoskeleton during the static and dynamic rehabilitation sessions with the…
- Trial name
- NCT04837144
- Testing
- Physical Rehabilitation with MAK exoskeleton
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- MarsiBionics
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Stroke
A Multi-center, Non-interventional Prospective Clinical Trial to Evaluate the Safety and Effectiveness of CVA-FLOW
CVAid Medical Ltd. developed a smartphone-based tele stroke system named CVA-Flow. This system aims to evaluate the patient's neurological status, particularly detection of a possible stroke, assessment of stroke severity, and…
- Trial name
- NCT06101004
- Testing
- CVA-Flow
- Where
- 2 sites in United States, Spain
- Volunteers
- 460 people
- Sponsor
- Cvaid Medical
Acute Ischemic Stroke
DAISe 1 Feasibility Study to Evaluate the DAISe Thrombectomy System for Acute Ischemic Stroke
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 36 subjects. The maximum enrollment is 10 subjects per site. A maximum of 6 investigational centers in Europe will participate.
- Trial name
- NCT05139147
- Testing
- DAISe Thrombectomy System
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- MIVI Neuroscience, Inc.
Acute Ischemic Stroke
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
Prospective, single-arm, multi-center study to confirm the performance and safety of the iNstroke 6F and 4F thromboaspiration catheter for the treatment of acute ischemic stroke
- Trial name
- iNDUO (NCT07376447)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in France, Germany
- Volunteers
- 160 people
- Sponsor
- iVascular S.L.U.
Prevention of Thromboembolic Events, Atrial Fibrillation
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function
Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: an irregular and often rapid heartbeat a blocked blood flow to the heart a blocked or reduced blood flow to a part…
- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation, Acute Myocardial Infarction, Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05419635
- Testing
- Asundexian (BAY2433334)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Spasticity, Post-Stroke
JCP Study of Investigation of Patient Background Characteristics
To collect the background characteristics of juvenile cerebral palsy patients aged 2-year or older prescribed BOTOX for the treatment of equines foot due to lower limb spasticity, compare them with those of patients whose deaths…
- Trial name
- NCT01332474
- Testing
- BOTOX
- Volunteers
- 326 people
- Sponsor
- GlaxoSmithKline
Acquired Brain Injury (Including Stroke)
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting
The primary objective of the study is to validate the safety and clinical performance of the ABLE Exoskeleton device in people with acquired brain injury during a 10-session gait training program in a clinical setting.
- Trial name
- NCT07050875
- Testing
- ABLE Exoskeleton
- Where
- 3 sites in Spain
- Volunteers
- 14 people
- Sponsor
- ABLE Human Motion S.L.
Acute Ischemic Stroke
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute…
- Trial name
- ACTION (NCT01955707)
- Testing
- natalizumab
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Biogen
The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation
WATCHMAN FLX™ CT Study
WATCHMAN FLX™ CT is a prospective, single-arm, single-center, post-market investigation to assess device tissue coverage in subjects with non-valvular atrial fibrillation (AF) who receive the WATCHMAN FLX device to reduce the…
- Trial name
- NCT05324371
- Testing
- Watchman FLX Device
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Stroke
DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
This study will be conducted in male and female subjects aged 18 to 80 years, inclusive, with non-valvular AF and a CHADS2 Score of at least 1. Subjects will be treated on an outpatient basis.
- Trial name
- NCT00806624
- Testing
- DU-176b tablets, Warfarin tablets
- Where
- 4 sites in China, Singapore and 2 more
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Stroke, Ischemic Stroke
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the…
- Conditions
- Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
- Trial name
- NCT01273337
- Testing
- ALD-401
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aldagen
Mild Cognitive Impairment, Alzheimer's Disease
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically…
- Trial name
- NCT01028053
- Testing
- Flutemetamol (18F) Injection
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- GE Healthcare